海普瑞(09989.HK)獲原副董事長孫暄增持64.3萬股公司H股
格隆匯5月18日丨海普瑞(09989.HK)公吿,深圳市海普瑞藥業集團股份有限公司(以下簡稱“海普瑞”、“公司”)於2021年5月7日披露了《關於董事辭職及計劃增持公司H股的公吿》(公吿編號:2021-021),基於對公司未來發展的信心及對公司價值的認可,公司原副董事長孫暄計劃自2021年5月7日起1個月內以自有資金從二級市場買入公司發行的H股,增持數量不低於64.3萬股。
近日,公司收到通知,上述增持計劃已完成。孫暄以自有資金從二級市場買入公司發行的H股,增持數量為64.35萬股,佔公司總股本的0.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.